-
Je něco špatně v tomto záznamu ?
Development and comprehensive comparison of two on-line capillary electrophoretic methods for β-secretase inhibitor screening
R. Řemínek, L. Slezáčková, J. Schejbal, Z. Glatz,
Jazyk angličtina Země Nizozemsko
Typ dokumentu srovnávací studie, časopisecké články
- MeSH
- aktivace enzymů účinky léků MeSH
- Alzheimerova nemoc enzymologie MeSH
- elektroforéza kapilární normy MeSH
- enzymatické testy přístrojové vybavení metody MeSH
- inhibitory enzymů farmakologie MeSH
- kinetika MeSH
- lidé MeSH
- objevování léků * MeSH
- sekretasy antagonisté a inhibitory MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
Alzheimer's disease is the most common cause of dementia, afflicting over 34 million patients worldwide. Since β-secretase is a rate-limiting enzyme of the production of neurotoxic β-amyloid peptide oligomers abnormally accumulated in the affected brain tissue, its specific inhibition appears to be a promising approach to slowing down or even stopping the progression of the disease. Hence two on-line capillary electrophoretic methods for studies of β-secretase activity based on the principles of transverse diffusion of laminar flow profiles and electrophoretically mediated microanalysis were developed, both using a simple unlabeled peptide substrate and UV detection. The optimized procedures were thoroughly validated and applied for determining the enzyme's kinetic parameters and the inhibition characteristics of two potent probe inhibitors. The resulting values were found to be comparable to literature data obtained with other analytical techniques. The suitability of the employed methodologies for different experimental designs is discussed on the basis of a statistical evaluation of the experimental data. The presented methods constitute a miniaturized and fully automated tool, which should be suitable for kinetic and inhibition studies of β-secretase as a target for Alzheimer's disease drug discovery in the early stages of the development of a new drug.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016370
- 003
- CZ-PrNML
- 005
- 20180515103846.0
- 007
- ta
- 008
- 180515s2017 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.chroma.2017.08.065 $2 doi
- 035 __
- $a (PubMed)28870543
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Řemínek, Roman $u Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 245 10
- $a Development and comprehensive comparison of two on-line capillary electrophoretic methods for β-secretase inhibitor screening / $c R. Řemínek, L. Slezáčková, J. Schejbal, Z. Glatz,
- 520 9_
- $a Alzheimer's disease is the most common cause of dementia, afflicting over 34 million patients worldwide. Since β-secretase is a rate-limiting enzyme of the production of neurotoxic β-amyloid peptide oligomers abnormally accumulated in the affected brain tissue, its specific inhibition appears to be a promising approach to slowing down or even stopping the progression of the disease. Hence two on-line capillary electrophoretic methods for studies of β-secretase activity based on the principles of transverse diffusion of laminar flow profiles and electrophoretically mediated microanalysis were developed, both using a simple unlabeled peptide substrate and UV detection. The optimized procedures were thoroughly validated and applied for determining the enzyme's kinetic parameters and the inhibition characteristics of two potent probe inhibitors. The resulting values were found to be comparable to literature data obtained with other analytical techniques. The suitability of the employed methodologies for different experimental designs is discussed on the basis of a statistical evaluation of the experimental data. The presented methods constitute a miniaturized and fully automated tool, which should be suitable for kinetic and inhibition studies of β-secretase as a target for Alzheimer's disease drug discovery in the early stages of the development of a new drug.
- 650 _2
- $a Alzheimerova nemoc $x enzymologie $7 D000544
- 650 _2
- $a sekretasy $x antagonisté a inhibitory $7 D053829
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a objevování léků $7 D055808
- 650 _2
- $a elektroforéza kapilární $x normy $7 D019075
- 650 _2
- $a aktivace enzymů $x účinky léků $7 D004789
- 650 _2
- $a enzymatické testy $x přístrojové vybavení $x metody $7 D057075
- 650 _2
- $a inhibitory enzymů $x farmakologie $7 D004791
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kinetika $7 D007700
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Slezáčková, Lucie $u Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Schejbal, Jan $u Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Glatz, Zdeněk $u Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic. Electronic address: glatz@chemi.muni.cz.
- 773 0_
- $w MED00004962 $t Journal of chromatography. A $x 1873-3778 $g Roč. 1518, č. - (2017), s. 89-96
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28870543 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180515104019 $b ABA008
- 999 __
- $a ok $b bmc $g 1299994 $s 1013210
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 1518 $c - $d 89-96 $e 20170826 $i 1873-3778 $m Journal of chromatography. A, Including electrophoresis and other separation methods $n J Chromatogr A $x MED00004962
- LZP __
- $a Pubmed-20180515